Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Individualized Neoadjuvant Chemoradiotherapy for Rectal Cancer Based on Recurrence Risk
NCT04664504Phase 2Recruiting
- Start
- Dec 2020
- Primary completion
- Dec 2022
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine, oxaliplatin in rectal cancer. Started Dec 2020; status: recruiting.
02
Drugs
capecitabineoxaliplatin
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT04664504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04664504.